What is SaNOtize Research & Development?
SaNOtize Research & Development is a global pharmaceutical entity focused on harnessing the antimicrobial capabilities of nitric oxide (NO). The company has engineered innovative products, including a nasal spray, designed to offer protection against viral pathogens. SaNOtize's technological advancements are of particular interest to healthcare providers and strategic partners seeking cutting-edge medical solutions. The company is dedicated to transparently communicating its technology and clinical development progress to potential investors and collaborators.
How much funding has SaNOtize Research & Development raised?
SaNOtize Research & Development has raised a total of $26.5M across 2 funding rounds:
Series A
$2.5M
Series B
$24M
Series A (2020): $2.5M with participation from OurCrowd
Series B (2022): $24M led by ABC International, OurCrowd, and Horizons Ventures
Key Investors in SaNOtize Research & Development
Horizons Ventures
Horizons Ventures is a venture capital firm that invests in deep science and technology aimed at advancing humanity. They focus on innovative projects with the potential for transformative change, particularly in the science and technology sectors.
OurCrowd
OurCrowd is an investment platform that enables accredited investors and institutions to invest in startups and early-stage companies. Based in Israel, they provide access to venture funds and promising businesses.
ABC International
ABC International is an entity that participated in SaNOtize Research & Development's Series B funding round, contributing to the company's strategic growth and market expansion.
What's next for SaNOtize Research & Development?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for SaNOtize Research & Development. This capital infusion is expected to accelerate the company's go-to-market strategies, potentially expanding its product reach and further validating its nitric oxide technology in the global healthcare market. Future developments will likely focus on scaling production, securing broader regulatory approvals, and forging new partnerships to solidify its position as a leader in antimicrobial solutions.
See full SaNOtize Research & Development company page
